DMK Pharmaceuticals On Oct 11, Got Notice From Nasdaq Co's Common Stock Was Subject To Delisting Unless Co Timely Requests Hearing Before Panel
Portfolio Pulse from Benzinga Newsdesk
DMK Pharmaceuticals received a notice from Nasdaq on October 11, stating that the company's common stock is subject to delisting unless the company requests a hearing before a panel in a timely manner.
October 17, 2023 | 8:41 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
DMK Pharmaceuticals is at risk of being delisted from Nasdaq unless it requests a hearing before a panel. This could potentially impact the company's stock price negatively.
The news of potential delisting is generally seen as negative by the market. It can lead to a decrease in investor confidence, which can result in a drop in the stock price. However, the final impact will depend on whether DMK Pharmaceuticals requests a hearing and the outcome of that hearing.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100